Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.
McGuire
Darren K
DK
Donald W Reynolds Cardiovascular Clinical Research Center, UT Southwestern Cardiology, Dallas, TX 75390-9047, USA. darren.mcguire@utsouthwestern.edu
D015415:Biomarkers / Q000097:blood; D002986:Clinical Trials as Topic / Q000379:methods; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology; D012107:Research Design; D018570:Risk Assessment; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D016896:Treatment Outcome
D015415:Biomarkers; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077154:Rosiglitazone; D045162:Thiazolidinediones; C517652:hemoglobin A1c protein, human